Gut Microbiome in Patients With Post-infectious Irritable Bowel Syndrome
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Trial code
- NCT07517029
- Record updated
- 13 April 2026
- Original description
Observational, multicenter, prospective study aimed at characterizing the gut microbiome in patients with post-infectious irritable bowel syndrome (PI-IBS) using whole genome sequencing (WGS). The study will compare microbiome composition and function between PI-IBS patients and two control groups (post-infectious subjects without irritable bowel syndrome -IBS- and healthy controls), with the goal of identifying reproducible microbial signatures and target taxa associated with disease and symptom severity.Read full original descriptionShow less
Informed Ecological Rewiring of Gut Microbiome for Dysbiosis-associated Disorders
Observational, multicenter, prospective study aimed at characterizing the gut microbiome in patients with post-infectious irritable bowel syndrome (PI-IBS) using whole genome sequencing (WGS). The study will compare microbiome composition and function between PI-IBS patients and two control groups (post-infectious subjects without irritable bowel syndrome -IBS- and healthy controls), with the goal of identifying reproducible microbial signatures and target taxa associated with disease and symptom severity.
PI-IBS patients (n = 105); Inclusion criteria; Age ≥ 18 years old; PI-IBS diagnosed according to Rome IV criteria (33); Diagnosis no earlier than 3 months before enrollment; Written informed consent and compliance with study procedures; Exclusion criteria; Chronic organic gastrointestinal (GI) disorders (e.g. Inflammatory Bowel Disease -IBD), metabolic syndrome, obesity, diabetes, GI cancers, systemic autoimmune disorders; History of major abdominal surgery; Control cohort #1 - Post-infectious non-IBS (n = 105); Inclusion criteria; Age ≥ 18 years old; History of acute infectious gastroenteritis >6 months before enrollment; Complete recovery without persistent GI symptoms; Exclusion criteria; Current or past diagnosis of IBS; Any chronic GI or systemic disorders; Control cohort #2 - Healthy subjects (n = 105); Inclusion criteria; Age ≥ 18 years old; Healthy donors from FMT program or blood donor program; No history of GI or systemic disorders; Exclusion criteria; Any GI or systemic chronic condition; Recent antibiotics/probiotics (<4 weeks); Chronic medication affecting microbiome composition (e.g. PPI).